Previous 10 | Next 10 |
2024-03-27 19:50:00 ET Summary Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said that the GLP-1 market could exceed $100 billion b...
2024-03-27 15:53:27 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by $2.46M Ligand Pharmaceuticals Q4 2023 Earnings Preview ...
2024-03-26 14:00:03 ET Justin Zelin from BTIG issued a price target of $125.00 for VKTX on 2024-03-26 11:20:00. The adjusted price target was set to $125.00. At the time of the announcement, VKTX was trading at $83.98. The overall price target consensus is at $45.33 with...
2024-03-26 14:00:03 ET Samimy Annabel from Stifel Nicolaus issued a price target of $95.00 for VKTX on 2024-03-26 10:57:00. The adjusted price target was set to $95.00. At the time of the announcement, VKTX was trading at $83.87. The overall price target consensus is at ...
2024-03-26 11:28:22 ET Shares of Viking Therapeutics (NASDAQ: VKTX) had skyrocketed by 25% as of 11:08 a.m. ET on Tuesday. That big gain came after the company announced results from a phase 1 clinical study evaluating an oral formulation of its experimental obesity drug VK2735. ...
2024-03-26 10:07:00 ET When it comes to rising stars in biotech, Viking Therapeutics (NASDAQ: VKTX) should probably be one of the first businesses to come to mind today. The company doesn't yet have any sales revenue, but its pipeline of metabolic disease drugs has more than one hig...
2024-03-26 09:20:00 ET U.S. stock index futures on Tuesday pointed to a slightly higher open, as market participants received a host of economic data and looked ahead to a week of speeches from Federal Reserve speakers. Here are some stocks to watch on Tuesday: ... Read the f...
2024-03-26 09:05:48 ET Viking Therapeutics Inc (NASDAQ: VKTX) is up nearly 20% on Tuesday after reporting encouraging early-stage data for its experimental weight-loss oral drug. Is Viking Therapeutics’ oral weight-loss drug effective? The biotechnology company said its c...
2024-03-26 07:37:54 ET More on Viking Therapeutics Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics: Here To Stay In Obesity, Or A Flash In The Pan? Viking Therapeutics: VK2735 Data Supports A Buyout Jefferies start...
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 PR Newswire Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
2024-07-20 06:00:00 ET California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them. Three Motley Fool contributors think they've found bi...
2024-07-19 05:50:00 ET Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally, the company would have a pipeline featuring multiple promising candid...
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 PR Newswire Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO , July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc...